ArticleJournal of managed care & specialty pharmacy2021
Removal of prior authorization for medication-assisted treatment: impact on opioid use and policy implications in a Medicare Advantage population.
Article in Journal of managed care & specialty pharmacy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Navigating opioid use disorder treatment for pregnant and parenting people: composite narratives for policy action.Substance abuse treatment, prevention, and policy · 2026Article
- State Laws Banning Prior Authorization For Medications For Opioid Use Disorder Increased Substantially, 2015-23.Health affairs (Project Hope) · 2025Article
- Medicaid managed care restrictions on medications for the treatment of opioid use disorder.Health services research · 2025Article
- Prior authorization restrictions on medications for opioid use disorder: trends in state laws from 2005 to 2019.Annals of medicine · 2023Article
- Changes in Medicaid Fee-for-Service Benefit Design for Substance Use Disorder Treatment During the Opioid Crisis, 2014 to 2021.JAMA health forum · 2023Article
- Thematic Analysis of State Medicaid Buprenorphine Prior Authorization Requirements.JAMA network open · 2023Review
- Buprenorphine Treatment For Opioid Use Disorder: Comparison Of Insurance Restrictions, 2017-21.Health affairs (Project Hope) · 2023Article
- The Future of the United States Overdose Crisis: Challenges and Opportunities.The Milbank quarterly · 2023Article
- Coverage and Prior Authorization Policies for Medications for Opioid Use Disorder in Medicaid Managed Care.JAMA health forum · 2022Article
- A modified Delphi process to identify experts' perceptions of the most beneficial and harmful laws to reduce opioid-related harm.The International journal on drug policy · 2022Article
- Association of Medication-Assisted Therapy with New Onset of Cardiac Arrhythmia in Patients Diagnosed with Opioid Use Disorders.The American journal of medicine · 2022Article
- Buprenorphine Use Trends Following Removal of Prior Authorization Policies for the Treatment of Opioid Use Disorder in 2 State Medicaid Programs.JAMA health forum · 2022Article
- The Role of the Pharmacist in Combating the Opioid Crisis: An Update.Substance abuse and rehabilitation · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.